Rapid pricing and market access assessment for an in-licensing opportunity
Determining the potential price and reimbursement status of a prospective business development asset.
Our client required a rapid pricing and market access (PMA) assessment across the US and EU5 for a potential Business Development (BD) opportunity. The project outputs were key inputs for the financial forecast and due diligence process to support a GO/NO-GO decision for in-licensing the novel biologic opportunity.
We utilized our ‘Pricing and Market Access Rapid Review’, which consists of 10 critical PMA parameters that payers consider when evaluating a product. We analyzed the pricing and market access landscape to address these 10 parameters. We then mapped the asset’s clinical and economic payer evidence to each pricing and market access parameter. As a result, we could provide a potential price range and determine the payer evidence requirements for the asset.
Value to the client
The target price range for the asset was utilized in the BD revenue forecast to determine whether to purchase the asset. Additionally, the payer evidence requirements were used to inform potential phase III trial designs to optimize future price and reimbursement for the asset.
The project outputs and recommendations supported our client in making their GO/NO-GO decision for in-licensing the novel biologic opportunity.
Remap Consulting were highly responsive to the customer’s needs, had great subject matter expertise and produced a lot of great content for us in a very short timeframe. They are a great partner for training development.
It was excellent work, very thorough. This was an essential input into our decision-making process for this opportunity.
Head of Market Access